Business
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
LYON, France, March 31, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and certain rare diseases, today announced that it has entered into a definitive agreement with SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company A U.S. pharmaceutical company specializing in the develo
About this update from Poxel Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/62b32c65a8560d47bcd6cd45b59a228a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h1_QO3LDTMX3ukdXAn.Hqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMg--/https://media.zenfs.com/en/business-wire.com/62b32c65a8560d47bcd6cd45b59a228a","width":480,"height":256}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"PXL770, a first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK), is a clinical-stage drug candidate targeting the underlying mechanisms of autosomal dominant polycystic kidney disease (ADPKD) by reducing cyst growth and disease progression","length":276,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Poxel will receive an upfront payment of $8 million, with an additional short-term payment of up to $8 million related to development milestones, and payments of up to $180 million related to commercial milestones","length":213,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"A Phase 2 proof-of-concept study in patients with ADPKD is expected to begin in the fourth quarter of 2026, with a first efficacy review expected in the second half of 2027.","length":173,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":662,"olType":false},{"type":"text","content":"LYON, France, March 31, 2026--(BUSINESS WIRE)--Regulatory News:","length":63,"tagName":"p"},{"type":"text","content":"POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and certain rare diseases, today announced that it has entered into a definitive agreement with SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company A U.S. pharmaceutical company specializing in the development of innovative new therapies for severe rare diseases, in connection with the sale of its drug candidate PXL770 (which will be renamed SCY-770).","length":602,"tagName":"p"},{"type":"text","content":"PXL-770 is a novel, highly selective, direct AMPK activator developed for the treatment of autosomal dominan...